BeiGene Presents Positive Interim Data from Trial of RAF-Inhibitor

BeiGene, a Beijing oncology company, reported positive initial data from a continuing Phase I trial of BGB-283 in patients with BRAF or KRAS/NRAS-mutated cancers. At the time of data cutoff, 29 pre-treated patients were available for analysis. There was one complete response from the 40 mg cohort, two partial responses in the 20 mg or 30 mg cohorts and 15 patients with stable disease that have sometimes extended over one year. BGB-283 is one of two drug candidates BeiGene has partnered with Merck KGaA, though it still holds China rights to the candidate. More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //